BoSS Teaming Profiles
This page is designed to help facilitate connections between prospective proposers, which ARPA-H anticipates will be necessary to achieve the goals of the BioStabilization Systems (BoSS) program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal.
If either you or your organization are interested in teaming, please create a profile via the ARPA-H Solutions Portal linked below. Your details will then be added to this page, which is publicly available.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.
BoSS Teaming Profiles
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| A | AA | AAA | AAA | AAA | AAA | AAA |
| Joseph Cohn | ACCELINT | joseph.cohn@soartech.com | Ann Arbor, MI | Our research focuses on AI-enabled decision support, modeling, and analytics for complex, distributed systems. We develop digital platforms for logistics, readiness, and supply-chain orchestration, including data integration, predictive modeling, and system-of-systems optimization, for scalable deployment and system integration (TA2). In healthcare, we focus on AI-enabled decision support and platform architectures, emphasizing translating research into operational and commercial settings. | We seek partners leading TA1 BioPrep efforts, including cell biology, biostabilization, biomaterials, and re-animation methods. We also seek TA2 partners with expertise in cell-friendly bioprocessing hardware, GMP-scale manufacturing, and regulatory translation. Our goal is to integrate core biological innovations into scalable, deployable bioprocessing platforms. | TA2: Bioprocessing, TA1: BioPrep |
| Robert ietswaart | Aircyt, Inc. | robert.ietswaart@aircyt.com | Boston, MA | AI for Cell Therapy discovery and manufacturing optimization, including biopreservation. | Automated, high-throughput lab testing, manufacturing, and commercialization partners. | TA1: BioPrep, TA2: Bioprocessing |
| Laura Bronsart | Ambient Biosciences | lbronsart@ambientbio.com | Ann Arbor, MI | Ambient Biosciences offers innovative stabilization technology designed to remove cold-chain constraints and provide a faster, more reliable alternative to lyophilization. Our freeze-free platform preserves biomolecular performance and lowers logistics costs while fitting seamlessly into existing manufacturing. With broad applicability to future cell-based products, Ambient supports partners aiming to expand scalability and advance ambient-ready workflows. | Ambient Biosciences aims to team with GMP cell and gene therapy manufacturers and groups experienced in engineered cells, viability testing, and functional potency assays. Partners will help assess how CAV’s innovative stabilization technology can interface with cell processing, formulation, and scale-up to advance ambient-temperature solutions for resilient and deployable cell-based products. | TA1: BioPrep, TA2: Bioprocessing |
| Maeva Coste | BioWraptor | mcoste@gc.cuny.edu | New York, NY | BioWraptor develops a peptide-based encapsulation technology to stabilize fragile biomolecules, including enzymes, proteins etc. at room temperature. The technology forms a protective coating in solution and enables stable dry powders. Research focuses on preserving structure and activity during formulation, drying, and storage, eliminating cold-chain dependence and improving resistance to environmental stresses. Current work includes long-term testing and pilot validation. | BioWraptor seeks teaming partners with capabilities in diagnostics, biosensors, and biologics manufacturing who can define mission-relevant use cases, support rapid pilot testing, and validate performance under operational constraints. We value partners with access to realistic deployment environments, scale-up or integration expertise, and a willingness to co-develop solutions that eliminate cold-chain dependence for health readiness. | TA1: BioPrep, IV&V Partner |
| Asher Williams | Columbia University | aw3571@columbia.edu | New York, NY, USA, NY | Our lab engineers protein–glycan interactions for therapeutic and diagnostic applications. Current work includes lectin engineering, nanobody–glycan conjugates, biomanufacturing of glycoproteins, and immune-modulating platforms for cancer, infection, and neurodegeneration. | We seek partners with expertise in cell stabilization, cryopreservation alternatives, materials for protective matrices, and scalable biomanufacturing. We are also interested in collaborators with capabilities in systems engineering, microfluidics, and in vitro functional assays to enable room-temperature stabilization and functional testing of engineered cells. | TA1: BioPrep, TA1: BioPrep |
| David Grimm | DesiCorp, Inc. | david.grimm@desicorpinc.com | Louisville, KY | DesiCorp, Inc (DCI) is led by Dr. Brett Janis, an expert in cell modification, anhydrobiosis, and cell preservation. DCI specializes in dry-state stabilization of biologics, manufacturing solutions, dry packaging, and cellular compound loading. DCI offers dry processing of cells for long-term storage and rapid reconstitution using an FDA-compliant dual-chamber bag. DCI is supported by bioprocessing-related programs (MTEC, DARPA) and can leverage this relevant experience for the BoSS program. | DCI collaborates with experts in anhydrobiosis (Dr. Michael Menze, UofL), cell lyophilization (Dr. Zhengrong Cui, UT Austin), and thin-film freeze-drying scale-up (Dr. Zachary Warnken, Via Therapeutics). We are seeking teaming partners with expertise in pharmaceutical preconditioning (metabolic stasis) and stochastic or evolutionary process optimization. Partner(s) in these areas will accelerate the project timeline and strengthen the team to deliver on the expectations of the BoSS program. | TA1: BioPrep, TA2: Bioprocessing |
| Abhinav Bhushan | Illinois Institute of Technology | abhushan@iit.edu | Chicago, IL | Biomedical research, cell based technologies | Validation assays | TA1: BioPrep, TA2: Bioprocessing |
| Rauf Ashraf | IPS HEART | rauf@ipsheart.com | Houston, TX | We have 2 FDA designed Orphan Drug Designated therapeutics which are iPS stem cell derived for making new cardiac muscle and new skeletal muscle. Our IND will be filed next year as the FDA has accepted our proposed Phase I/II clinical trial endpoints. | Cryopreservation, recovery, etc | TA2: Bioprocessing, TA1: BioPrep |
| Tim Obara | Jurata Thin Film Inc | tobara@juratatf.com | Chapel Hill, NC | Jurata’s stabilization technology utilizes polymeric excipients to stabilize biologics, including cells, preserving their structural integrity and bioactivity. The underlying mechanism of stabilization is attributed to the formulation’s ability to prevent aggregation and hydrolysis. Studies have shown that Jurata’s technology significantly enhances the stability of live-attenuated viral vector vaccines under accelerated storage conditions, enabling long-term viability at ambient temperatures. | Jurata is looking for partners that have demonstrated capabilities in bioprocessing. Partners that would add capabilities to our stabilization technology, including re-animation techniques or reversible suspension of biological activity would be ideal to optimize the benefits of our technology, | TA2: Bioprocessing, TA1: BioPrep |
| Joe Larsen | Kensington Street Consulting | jlarsen@kensingtonst.com | Arlington, VA | We provide proposal writing support and technical program/agreement management post-award. We are looking for additional partners to join our team. | We are looking for teaming partners for TA2 Bioprocessing. | TA1: BioPrep |
| Lisa Stehno-Bittel | Likarda | lbittel@likarda.com | Kansas City, MO | Likarda developed a novel microencapsulation process using well-characterized, biocompatible polymers to protect cell therapies. The technology was first used to deliver cells providing immune protection or slow, targeted release. As we applied the technology more, the ability to protect cells during storage in harsh conditions became apparent. The process improves survival during cryopreservation and fresh cell storage, extending the shelf life and can be dissolved-on-demand by the end users. | Likarda’s proposal focuses on the promise of cell lyophilization using our polymers to protect the cells. We are looking for team members that would 1) have unique methods of testing the cellular function and stability after lyophilization, 2) have a compelling need for lyophilized cells and 3) companies that could design a GMP-ready version of our alpha unit. | TA1: BioPrep, TA2: Bioprocessing |
| Sheila Mikhail | M34 | mscott@m34thx.com | Chapel Hill, NC | M34 is a clinical-stage AAV gene therapy company improving safety, efficacy, and cost. Its redesigned Zolgensma for SMA showed in humans a 1/60 dose reduction. At this dose, one 200-L bioreactor could supply all global SMA patients. Since manufacturing drives gene therapy costs, M34’s approach can significantly lower treatment expense. | M34 is looking for partners that have demonstrated capabilities in bioprocessing in cell based platforms, including thermo-stabilization. Capabilities that include innovative upstream and downstream approaches, including suspension based platforms are preferred. | TA1: BioPrep, TA2: Bioprocessing |
| Jennifer Buell | MiNK Therapeutics | jennifer.buell@minktherapeutics.com | Lexington, MA | MiNK Therapeutics is a cutting-edge clinical-stage company developing innovative allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The lead product is an off-the-shelf therapy administered without lymphodepletion or HLA matching. These cells enhance both innate and adaptive immunity by combining the potent cytotoxicity of natural killer (NK) cells with the lasting memory response of T cells. | MiNK's lead product candidate AGENT-797 is in multiple Phase 1 clinical trials with clinical and preclinical readouts anticipated later this year. Our research team is focused on developing potential first-or best-in-class therapies using a next- generation technology platform to develop novel engineered iNKT cell therapies and bispecific iNKT cell engagers. | TA2: Bioprocessing, TA1: BioPrep |
| Joseph Russell | MRIGlobal | jrussell@mriglobal.org | Gaithersburg, MD | biosecurity, applied Bio-engineering, automated device development, computational biology, AIxBio | Genome engineering, extremophile biology | TA2: Bioprocessing, TA1: BioPrep |
| Roger Narayan | North Carolina State University | roger_narayan@ncsu.edu | Raleigh, NC | my focus involves the use of inkjet printing, matrix assisted pulsed laser evaporation, and laser induced forward transfer to process biological materials for medical applications | appropriate partners for evaluating our processing technology | TA2: Bioprocessing, TA1: BioPrep |
| Leila Deravi | Northeastern University | l.deravi@northeastern.edu | Boston, MA | Our team has expertise in the formulation design, lab-scale fabrication, and testing of bio-inspired materials and coatings suitable for cell/biomolecule encapsulation. Expertise in biomaterials, polymer chemistry, thin film and 3D fabrication (printing and controlled emulsion polymerization in coatings) with lab-scale testing of biologics under extreme environments available and validated for use. | Looking for partners who can help scale lab-based solutions and experimentally validate bioactivity under our confinement conditions and assays | TA2: Bioprocessing, TA1: BioPrep |
| Mahdi Imani | Northeastern University | m.imani@northeastern.edu | Boston, MA | Northeastern University develops advanced autonomous decision systems, adaptive learning frameworks, and safety-certified reasoning models for large-scale health and cyber-physical environments. Our research integrates symbolic and high-dimensional representations, uncertainty quantification, and distributed AI to enhance national health preparedness and resilient response. | Our group focuses on autonomous decision-making, symbolic and high-dimensional reasoning, PAC-Bayesian safety methods, and adaptive AI for health systems. We develop scalable models for preparedness, early detection, distributed inference, and resilient response across complex, uncertain health environments. | TA1: BioPrep |
| Benjamin tenOever | NYU School of Medicine | Benjamin.tenOever@NYUlangone.org | New York, NY | We develop a programmable RNA vector platform that delivers large genetic payloads, supports logic gated expression, achieves broad tissue distribution, and can be stored in a stable lyophilized format for field ready use. Our work integrates innate immunity, gene editing, and next generation therapeutic and diagnostic design. | We seek collaborators with expertise in formulation, biomaterials, device integration, regulatory planning, or specialized therapeutic areas. Partners who can expand payload applications or support translation of our RNA vector platform are especially valuable. | TA1: BioPrep, TA2: Bioprocessing |
| Donghoon Lee | Omphalos Lifesciences | donghoon.lee@omphaloslifesci.com | Dallas, TX | We built a high-performance mechanistic modeling engine for whole-cell biology and executable bacterial cell models predicting genetic and chemical perturbation responses. For BoSS we will extend to human cells to simulate stabilization, storage, and reanimation end-to-end, diagnose failure modes, infer hard-to-measure state shifts from observed outcomes, and guide specific fixes and follow-up tests. Teammates get faster down-selects, tighter operating windows, and fewer wet-lab cycles. | TA1: BioPrep teams with a defined stabilization and reanimation approach and shareable time-series datasets with full condition metadata and outcomes (including strong and weak performance) so we can fit and validate predictive models. TA2: Bioprocess and device teams with a defined workflow and product specifications, plus unit-operation parameters and run data, so we can connect BioPrep choices to end-to-end process performance. | TA1: BioPrep, TA2: Bioprocessing |
| Derese Getnet | Simmbion | dgetnet@simmbion.org | Baltimore, MD | Simmbion is pioneering a trypanosome-based "living medicine" platfrom designed to transform the delivery of biologics (peptides, enzymes, and antibodies) through a single once-yearly injection that dramatically improves compliance, cost-effectivness, and removes cold chain for patients. current formulation of this cell therapy is stable for 15 days at room temprature and 1 month at 4C. With support from NSF, Simmbion has recieved concurrence from FDA through INTERACT meeting a 2 study BLA path. | Having been inspired by nature on symbiosis, we are looking for partners that have automated screening capabilities to survey novel formulations derived from the salivary gland and hemolymph of the kissing bug. | TA1: BioPrep, TA1: BioPrep |
| Jon Hibshman | Southern Methodist University | jhibshman@smu.edu | Dallas, TX | Our main goals are to understand how some cells and organisms can survive desiccation and to deploy these evolved solutions to protect biological materials in the dried state. We have experience and expertise with protectant discovery with innovative screening approaches, validation of new types of protectants in vitro and in heterologous systems, and deciphering mechanisms of protection in vivo. | We are looking for teaming partners with capabilities to scale up formulation and delivery of protectants and the ability to test their protective capacity with a wider variety of cells and biological materials that are candidates for preservation in the dried state. | TA1: BioPrep, TA2: Bioprocessing |
| Shahar Sukenik | Syracuse University | ssukenik@syr.edu | Syracuse, NY | We aim to uncover the molecular grammar underlying desiccation tolerance in biological systems. Our research is driven by two main thrusts: The first thrust aims to uncover the sequence properties that allow proteins to tolerate desiccation and rehydration. The second thrust aims to design novel, protective intrinsically disordered proteins that confer cells and organisms with desiccation protection. | We develop high throughput methods to study desiccation protection at scale. We are looking for partners to help us validate hits from our screens. Specifically, we would be interested in creating desiccation tolerant variants of specific protein-based therapeutics, or by adding protective proteins as excipients to formulations that currently require cold-chain delivery. | TA1: BioPrep, TA2: Bioprocessing |
| Alan Rudolph | Tardigrada Technology Group | Rudolph@colostate.edu | Denver/Front Range, NY region, CO | Our experience covers the science of stabilization to its applications in biological formulation development. Experience includes stabilizing blood cells, and engineering nucleated cells as DARPA PM, corporate development (Cellphire) and dry stabilization of vaccines and proteins. | Looking to support teams in development | TA2: Bioprocessing, TA1: BioPrep |
| Zhengrong Cui | The University of Texas at Austin | Zhengrong.cui@austin.utexas.edu | Austin, TX | UT Austin offers its proprietary dry powder compositions of eukaryotic cells enabled by thin-film freeze-drying (TFFD). Dry powders of human monocytes or murine tumor cells, prepared using our TFFD technology, maintain cell viability and are room-temperature stable. Via Therapeutics provides the specialized equipment and large-scale resources necessary to commercialize this process, led by a team with a proven track record of successfully scaling TFFD technology for other applications. | The UT Austin-VIA team collaborates with partners with expertise in anhydrobiosis (Dr. Menze, UofL), aseptic manufacturing and innovative packaging solutions (Dr. Janis, DesiCorp), and cellular compound loading (e.g., sonoporation, DesiCorp). We also welcome partners with other validated cell loading and/or cell BioPrep technologies (e.g., magnetoporation, Sigma Genetics) to condition cells for TFFD and seek partners with experience in the regulatory aspects of cell and gene therapy products. | TA2: Bioprocessing, TA1: BioPrep |
| Jonathan (Jack) Reid | Unicorn Biotechnologies | jack.reid@unicornb.io | Newark, NJ | Unicorn Biotechnologies develops autonomous, closed-loop platforms for scaling mammalian cellular bioproduction. Our core focus is machine intelligence (AI)-driven stabilization, expansion, and process control of living cells, integrating robotics, real-time sensing, and agentic AI to improve yield, reproducibility, and deployability of advanced biologics, including cell therapies and cell-derived products. | We seek partners with breakthrough cell stabilization, preservation, or materials technologies; expertise in dry/ambient storage, intracellular protectants, or novel processing methods; and groups strong in translational biology, regulatory strategy. Ideal partners complement our autonomous manufacturing and AI control stack to enable end-to-end BoSS systems. | TA2: Bioprocessing, IV&V Partner |
| Ting Xu | University of California, Berkeley | tingxu@berkeley.edu | Berkeley, CA USA, CA | We have developed materials called random heteropolymers for protein and serum stabilization under various conditions. Detailed can be found in the following publications: Random Heteropolymer Enables Protein Function in Foreign Environments, Science, 2018, 359, 1239; Population-based Heteropolymer Design to Mimic Protein Mixtures in Biological Fluids, Nature, 2023, 615, 251. | Industrial partner with clinically relevant biological entities. | TA1: BioPrep, TA2: Bioprocessing |
| Maxwell Wilson | University of California, Santa Barbara | mzw@ucsb.edu | Santa Barbara, CA | High-throughput, robotics, synthetic biology, cell engineering, deep learning | biopreservation expertise | TA1: BioPrep, TA2: Bioprocessing |
| Allen Liu | University of Michigan | allenliu@umich.edu | Ann Arbor, MI | My lab recently showed a stress-responsive intrinsically disordered protein from tardigrades reinforces membrane integrity in synthetic cell membrane and preserves encapsulated components, mimicking natural anhydrobiosis (biorxiv.org/content/10.1101/2025.08.07.669088v1). This finding opens up a protein-based strategy to impart synthetic cells with resilience to desiccation, expanding their utility in bioengineering, cold-chain-independent biomanufacturing, and adaptive biointerfaces. | Looking for researchers who want to leverage these proteins for removing the cold chain from cell-based therapies. | TA1: BioPrep, TA2: Bioprocessing |
| Christy Haynes | University of Minnesota | chaynes@umn.edu | Minneapolis, MN | My research group has experience designing and synthesizing nanomaterials that facilitate rewarming after cryopreservation. It would be interesting to consider whether these polymer-functionalized nanomaterials could be adapted (by changing the core nanomaterial or appended polymer) so that they preserve structure/function after room temperature storage, as requested in BoSS. We have also worked on significant nanomaterial scale-up for previous applications. | This area of room temperature storage is new to my research group, so I would be interested in teaming partners who have the biological expertise and/or hardware (for reactivating preserved biologics) expertise. | TA1: BioPrep |
| Alexander Kabanov | University of North Carolina at Chapel Hill | kabanov@email.unc.edu | University of North Carolina at Chapel Hill, NC | Innovative polymer solutions for drug delivery, nanomedicine, and phramacoengineering. Our nanotechnology center accelerates the efficacy of new drugs and imaging agents and translates leading-edge nanomedicine into clinical solutions for diseases with limited treatment options. | Industrial partners capable of scale up our polymer based processes fro biopharmaceuticals | TA1: BioPrep, TA2: Bioprocessing |
| Thomas Boothby | University of Wyoming | tboothby@uwyo.edu | Laramie, WY | We focus on understanding how organisms survive extreme desiccation and how we can adapt these strategies for the stabilization of biologics outside of the cold-chain. Specific areas of interest include understanding what material properties of vitrified systems enhance protection during drying and prolong protection once in the dry state. | We specifically seek teaming partners with expertise in functional testing of biologics and/or delivery of exogenous vitrifying material into cells, tissues, or whole organisms. | TA1: BioPrep, TA2: Bioprocessing |
| Eric Claude | MPR Associates | eclaude@mpr.com | Alexandria, VA | MPR's Health and Life Science Team provides services for design, development, engineering, and testing for medical devices, diagnostic instruments, and pharma/biopharma manufacturing. We use risk-based approaches to develop bespoke processes, devices, and test equipment to ensure safety, reliability, and regulatory compliance. With our team of 250 engineers, designers, and scientists, MPR’s expertise supports translation of innovations from lab to commercial production. | MPR seeks to partner with prime performers who wish to leverage our capabilities to reduce risk and accelerate development through: technology evaluation, solution definition, rapid development for bench-top feasibility and risk reduction, design and development of commercial-ready devices, testing/validation, and preparation of FDA-required documentation. | TA1: BioPrep, TA2: Bioprocessing, IV&V Partner |
| Kyle Knouse | Broken HIll Ventures | kyle@brokenhill.bio | San Diego, CA | Cryptobiosis and cellular protection | TBD | TA1: BioPrep, TA2: Bioprocessing |
| Girija Goyal | Wyss Institute | girija.goyal@wyss.harvard.edu | Boston, MA | Creating a multi-immune cell therapy to create localized immune hubs in solid tumors | Manufacturing experience or desire to innovate in cell therapy particularly for non-T cells | TA1: BioPrep, TA1: BioPrep |
| Zacharyr Warnken | Via Therapeutics | Zwarnken@viatherapeutics.com | Austin, TX | Via Therapeutics utilizes novel formulation and processing technologies to overcome critical barrier to treating clinically unmet needs. This ranges from inhaled therapeutics for infectious disease to stabilizing biologics and vaccines for room temperature storage. | We are looking for teams with resources in preparing cells prior to drying. Specifically, those with high-throughput and computational methods of designing and analyzing experiments to reach the end goal. | TA2: Bioprocessing, TA1: BioPrep |
| David Mead | Varigen Biosciences dba Varizymes | dmead@varigenbio.com | Middleton, WI | Genome mining, protein expression, purification, and assay development | Cellular stability assays and applications | TA1: BioPrep, TA2: Bioprocessing |
| Pavan Muttil | College of Pharmacy, University of New Mexico | pmuttil@salud.unm.edu | Albuquerque, NM | Our research focuses on stabilizing vaccines using spray drying technology, including live bacterial vaccines, cancer cells, antigens, subunit vaccines, and virus-like particles. Inspired by natural desiccation processes, we use thermo-protective excipients such as sugars (e.g., trehalose) to maintain biological integrity. Our vaccine stabilization work has been funded by the Gates Foundation, the US Department of Defense, and NIH. | We seek teaming partners capable of supplying diverse biologics to support stabilization process development, with a shared goal of advancing successful technologies toward scalable deployment and a future GMP manufacturing facility. | TA2: Bioprocessing, TA2: Bioprocessing |
| Michael Balanovskiy | BioManufacturing Solutions | m.balanovskiy@biomanufacturingsolutions.com | Toronto, Canada and Los Angeles, California, CA | BioManufacturing Solutions focuses on applied research and execution at the intersection of regulatory science, quality systems, and biomanufacturing readiness. Our work is centred on translating emerging health technologies from research environments into compliant, scalable, and deployable solutions. This includes regulatory pathway development, quality system design, GMP and clean room planning, and manufacturing strategies to support clinical/commercial deployment. | BMS seeks partners with strong technical or scientific expertise who are focused on translating innovation into the real world/commercialization. We value partners who prioritize high quality that meet regulatory standards. Outcome focused teams. | TA1: BioPrep, TA2: Bioprocessing, IV&V Partner |
| ARMON SHAREI | Portal | armon@portal.bio | Boston, MA | Portal is commercializing a novel cell engineering platform capable of delivering virtually any material into any cell type at scale | While Portal has deep expertise in providing point-of-care cell engineering solutions, we would be excited to team up with partners with biological insights that can help achieve the project goals and ensure maintenance of cell function | TA2: Bioprocessing, TA1: BioPrep |
| Achraf Noureddine | University of New Mexico | anoureddine@unm.edu | Albuquerque, NM | For the BoSS program, my research emphasizing cell armoring using soft, hard or hybrid chemical entities is most relevant. Other topics include drug and gene delivery, cancer immunotherapy. | Research expertise in high-throughput bioprocessing, AI/ML predictive models, and required chemistry to stabilize cell membrane and organelle upon dessication. | TA1: BioPrep, TA2: Bioprocessing |
| Bob Snyder | Proteios Technology, Inc. | bob@proteios.com | Seattle, WA | Proteios has developed an AI-based platform for the design of DNA/RNA aptamers. We have incorporated this technology into an aptamer-based cell isolation device for the rapid, cost-effective isolation of intact immune cells. It enables parallel enrichment/depletion of immune cells based on their selection using multiple surface antigen criteria. In addition, we have incorporated the technology into a fully automated, closed system for the end-to-end manufacturing of cell-based therapies. | Proteios is looking for teaming partners that can provide the downstream technology following cell isolation / cell therapy manufacturing to eliminate the need for ultra-cold storage. Alternatively, Proteios could pursue the development of an aptamer-based Point-of-Care (PoC) device for the decentralized manufacturing of cell-based therapies - removing the need for ultra-cold storage of antibody reagents and cell-based therapies. | TA2: Bioprocessing, TA1: BioPrep |
| Kunal Mehta | Ginkgo Bioworks | kmehta@ginkgobioworks.com | Boston, MA | Ginkgo is a biological engineering company based in Boston. We enable large-scale, systematic, model-driven, and unbiased exploration of massive genetic and process design spaces. Technical expertise relevant to BOSS includes high-throughput ML-driven protein engineering and screening with mammalian cell lines. We have also successfully managed numerous large/multiparty government programs and have experience with the entire process from proposal development to contracting and execution. | We are looking for partners with ingredients (proteins, polymers, etc.), process technologies, and other interventions that could form part of a preservation and reanimation solution (TA1) as well as partners with device design and engineering expertise (TA2; Ginkgo can complement here with integration of disparate devices) | TA1: BioPrep, TA2: Bioprocessing |
| Ravi Goyal | Epigenuity LLC | rgoyal@epigenuity.com | Tucson, AZ | Epigenuity LLC develops non-cryogenic preservation technologies for living cells and biologics. Our work integrates intracellular glass-forming protectants, engineered bio-glass formulations, oxidative suppression, and staged restoration to enable dry or refrigerator-stable storage of mammalian cells with functional recovery. We focus on scalable, deployable workflows that eliminate liquid nitrogen dependence. | We seek partners with expertise in lyophilization and formulation science, scalable bioprocessing and closed-system cell handling, materials science for high-Tg glasses or encapsulation, and analytical methods for moisture, Tg, and potency. Industrial, CDMO, or device partners interested in deployable, non-cryogenic cell processing systems are especially welcome. | TA1: BioPrep, TA2: Bioprocessing, IV&V Partner |
| Christopher Bowman | University of Colorado Boulder | grant.malone@colorado.edu | Boulder, CO | Our research groups focuses on the development and implementation of intracellular and extracellular approaches to altering biological activity through the use of synthetic, functional polymer molecules. | We are looking for partners that have the ability to process cells in a manner that encourages rapid uptake of polymeric molecules and subsequent water removal. | TA1: BioPrep, TA2: Bioprocessing |
| Advait Holkar | Praio | aholkar@praio.co | Praio makes Artificial Protocells in vitro by encapsulation of enzymes and nucleic acids in complex coacervate phases formed with synthetic polymers. These protocells mimic intracelluar biomolecular condensates while still maintaining the flexibility of cell-free systems. By combining advances in material science and synthetic biology, we design protocells for bespoke applications, such as intensified biomanufacturing of small molecules and biomaterial storage. | We are a biomaterial formulation company looking for partners with complimentary expertise in biologics, ranging from cell therapy, gene therapy and complex proteins. We envision a partnership where Praio formulates the biologic cargo for improved stability, activity or delivery | ||
| Jyoti Taneja | Varada Agriculture Inc. | jyotitaneja@varadaagriculture.com | Berkeley, CA | We develop RNAi-based biologicals for pathogen control, with an initial focus on agricultural pathogens. Our current research emphasizes RNA formulation technologies that eliminate cold-chain requirements, enabling room-temperature storage with 1-2 year shelf life. These formulations are designed for robustness, scalability, and adaptability across multiple biological applications. | We seek partners with expertise in formulation chemistry, materials science, and scalable manufacturing to translate RNAi concepts into deployable products. Ideal collaborators complement our strengths in RNA design, biological optimization, and stability testing with capabilities in formulation development, encapsulation, delivery systems, and process scale-up. | TA1: BioPrep, TA2: Bioprocessing |
| Weilong He | University of Texas at Austin | weilonghe@utexas.edu | Austin, TX | Our organization focuses on biomaterials-based strategies for stabilizing and formulating sensitive biologics, including proteins and viral vectors. We develop materials and processing approaches to improve storage robustness, shelf-life, and manufacturability of biologics under non-ideal conditions, with an emphasis on translation-relevant preparation and processing workflows. | We are interested in teaming with partners who bring complementary expertise in virology, protein engineering, formulation science, or biomanufacturing scale-up, as well as groups with capabilities in analytical characterization and real-world storage and deployment testing. | TA1: BioPrep, TA2: Bioprocessing |
| Rafael Badell | ClonalStem, INC | rafael@d1asp0ra.com | Madison, WI | We maintain a specialized stem cell bank of early-passage, cord blood-derived Endothelium Colony Forming Cells (ECFCs). These cells are a critical, high-sensitivity model for vascular repair and regenerative medicine. Our focus is on the standardized expansion of these low-passage progenitors to ensure high potency and biological integrity. Because ECFCs are notoriously sensitive to stressors, they serve as a "gold standard" stress-test for validating novel stabilization technologies. | We are seeking TA1 (BioPrep) partners developing chemical/biological stasis solutions and TA2 (Bioprocessing) teams building scalable hardware. We provide the authenticated, early-passage human cell assets required for rigorous testing. We also seek partners with established functional assay capabilities (e.g., tube formation, metabolic profiling) to validate cell potency post-stabilization. We aim to be a high-quality biological material provider for multidisciplinary teams. | TA1: BioPrep, TA2: Bioprocessing |
| Keerthi Prasad Venkataramanan | The Bioforge | keerthi@thebioforge.com | Vancouver, WA | We develop AI-driven, automation-enabled bioprocess optimization technologies for biologics, cell-based products, and bio-derived systems. Our work focuses on stabilizing critical quality attributes across upstream processing, formulation, and scale-up, enabling reproducible, manufacturable, and distribution-ready biological products under non-ideal conditions. | We seek bold, risk-tolerant partners pursuing non-traditional biostabilization approaches, including novel materials, cell-state engineering, and unconventional preservation strategies. Ideal teammates are willing to test aggressive hypotheses, generate rapid experimental data, and co-develop scalable systems that challenge cold-chain assumptions and enable step-change advances. | TA2: Bioprocessing, TA1: BioPrep |
| Abraham Joy | Northeastern University | a.joy@northeastern.edu | Boston, MA | Design of biocompatible polymers in translationally relevant quantities, Characterization of the interface between materials and biologics. | Biotech partners who can provide samples and knowledge of processes, translational hurdles and challenges. | TA2: Bioprocessing, IV&V Partner |
| Katie Kugler | Vivid BioInnovations | KKugler@vivid-bio.com | San Francisco, CA | Developing microfluidic, end-to-end cell biostabilization and reanimation workflows focused on deterministic single-cell handling, transient permeabilization, rapid CPA loading, ultrafast vitrification, controlled dehydration below Tg, and staged recovery. Building scalable cartridges/instrumentation to enable cold-chain-independent storage and distribution of living cell products | Seeking TA1 BioPrep partners with reversible intracellular protection strategies (e.g., trehalose/IDPs/other protectants), cell biology/cryobiology expertise, and validated reanimation formulations/SOPs to integrate with our TA2 platform. Also interested in GMP/aseptic manufacturing, regulatory/commercialization, and clinically relevant cell models to support BoSS metrics and IV&V readiness. | TA2: Bioprocessing, TA1: BioPrep |
| Mehmet Toner | Massachusetts General Hospital (The General Hospital Corp.) | mtoner@hms.harvard.edu | Boston, MA | Our laboratory has been at the forefront of biopreservation research for several decades. We are pursuing multiple strategies to induce suspended-animation states in living systems, including dry-storage under ambient conditions. We also maintain a strong focus on cell and gene therapy. We have developed complementary physicochemical and biological approaches to stabilize cells during preservation, as well as hight-throughput methods for intracellular delivery of large molecules to cells. | Our team has a strong background and expertise in engineering (especially heat and mass transfer at micro- and macro-scales), physicochemistry to facilitate dry storage, molecular and cellular biology including expertise cell therapy, and systems with natural desiccation-tolerance, positioning us to address both TA1 and TA2. We would be highly interested in identifying an IV&V partner. | TA1: BioPrep, TA2: Bioprocessing |
| Gokce Altin Yavuzarslan | Northeastern University Department of Chemistry and Chemical Biology | g.altinyavuzarslan@northeastern.edu | Boston, MA | The Altin–Yavuzarslan Lab focuses on engineered living materials (ELMs), integrating biocompatible polymer design, advanced cell encapsulation strategies, and additive manufacturing. We develop printable polymer networks and encapsulation platforms to fabricate 3D engineered living systems with enhanced viability and functionality for adaptive environments, sustainable bioproduction, smart materials, and therapeutic applications. | We are seeking teaming partners with expertise in synthetic biology, metabolic engineering, biosensing, and system-level integration to complement our strengths in engineered living materials and biofabrication. We are particularly interested in collaborators focused on scalable bioproduction, robust living systems, and translation of lab-scale technologies into deployable platforms. | TA1: BioPrep, TA2: Bioprocessing |
| Shukti Chakravarti | NYU Langone Health Grossman School of Medicine | shukti.chakravarti@nyulangone.org | New York, NY | We develop extracellular matrix (ECM) from stem cell-derived human cornea organoids with cell-supportive wound repair potential that can become an ambient temperature-stable xenofree regenerative tissue resource. Our de-cellularized organoid ECM can be lyophilized and ready for on-site use. | We seek collaborators interested in regenerative treatments of a broad array of organs and tissues to increase general applicability of our cell-free human ECM. Additionally, we seek partners for developing fluent translational workflow, scale-up and regulatory aspects. | TA1: BioPrep |
| Jelena Janjic | Nanomedicine Manufacturing Lab, Duquesne University | janjicj@duq.edu | Pittsburgh, PA | We develop oxygen and drug delivery nanomedicines and biomaterials, and protocols for human cell culture with optimized intracellular delivery that preserves cell function and metabolism. Our systems provide sustained and controled oxygen and drug delivery. We demonstrated tissue/cell preservation for >24h. We apply Quality by Design (QbD) and Design of Experiments (DOE) to develop, optimize, and validate nanomedicine manufacturing processes, with demonstrated liter-scale batch production. | We seek teaming partners that complement our oxygen and drug delivery BioPrep capabilities. Ideal partners include TA2 teams developing cell-friendly bioprocessing devices or instrumentation for scalable, closed-system deployment of biostabilization, and TA1 teams contributing novel intracellular protectants, re-animation biology, or functional recovery assays. Partners should enable integration into a cohesive, GMP-relevant BoSS platform without duplicating formulation expertise. | TA1: BioPrep, TA2: Bioprocessing |
| Xiaoxi(Sofie) Wei | X-Therma Inc. | xwei@x-therma.com | Hercules, CA | X-Therma specializes in the design, synthesis, and scale-up of nature-inspired peptidomimetics (i.e., peptoids) and have developed a versatile library of proprietary peptoid chemistries tailored for multiple preservation modalities, including cryopreservation, high subzero preservation, and emerging lyo-protection. Several formulations are GMP-ready and validated across clinically relevant cell and tissue types, enabling safer and more consistent off-the-shelf biological products. | X-Therma brings a peptoid platform that enables effective cell loading, conditioning, and protection during preservation workflows, and collaborates with leading immune and stem cells institutes. We seek teaming partners developing scalable, anhydrous biopreservation technologies (e.g., thin-film freeze-drying, spray-freeze drying) that have demonstrated initial preservation of mammalian cell viability where X-Therma's expertise can drive major gains in viability and functional recovery. | TA1: BioPrep, TA2: Bioprocessing |
| Xiling Shen | MD Anderson, Terasaki Institute | xilings@gmail.com | Houston, Los Angeles, TX | MD Anderson is developing various immune cell therapies for cancer and autoimmune diseases and tissue organoid models for diagnostics and therapeutic development. Terasaki Institute is developing organ transplant and cell-based regenerative technologies. | We look for Bioprep and Bioprocessing partners who will utilize our cell products as testbeds for scaling storage solutions. | TA2: Bioprocessing, TA1: BioPrep |
| Kevin Flynn | CaseBioscience | Kevin.Flynn@Casebioscience.com | Fort Collins, CO | Our R&D is focused on developing innovative media formulations for cell biopreservation, cell culture, and cell handling in cell therapy and assisted reproductive technologies (ART). The most pertinent project is the development of a highly effective hypothermic cell biopreservation solution for cell therapies. CaseBioscience is an FDA-registered, ISO13485:2016 certified manufacturer of Biosolutions, poised to deliver innovative research into clinical products. | We have identified potential teaming partners, but are mainly looking for partners in the Bioprocessing aspects of this application. Complimentary partners will have mastery of biomaterials, bioengineering, and closed system integration of cell stabilizing solutions/containers into a comprehensive workflow applicable for biomedical applications (e.g. Cell Therapy). | TA1: BioPrep, TA2: Bioprocessing |
| Tagbo Niepa | Carnegie Mellon University | tniepa@andrew.cmu.edu | Pittsburgh, PA, PA | Our team is developing nanoculture-based bioengineering platforms that enable long-term stabilization, protection, and functional control of living biological systems under harsh or fluctuating environmental conditions. Nanocultures are microengineered, semipermeable polymer compartments (nL-scale) that physically isolate biological payloads while permitting selective molecular exchange, enabling sustained viability, controlled interactions, and predictable function. | We are seeking for complementary expertise in preservation and extreme environments biology; autonomous control of biological systems; scale-up and deployment device engineering for clinical, environmental or defense-relevant applications; computational modeling and system-level optimization. | TA1: BioPrep, TA2: Bioprocessing, IV&V Partner |
| TAVIS EZELL | CUNY Advanced Science Research Center | tezell@gc.cuny.edu | New York, NY | CUNY's Advanced Science Research Center serves New York City and the surrounding area as a hub for translational research and houses 5 core science initiative with over 200 faculty, research staff, students, and administrators. ASRC operates 15 service-based facilities (from Nanofabrication to Sensors to Animal Vivarium), accessible to both academic and commercial users. An Industry Engagement office provides funding and operational support to shepherd commercial partners projects. | industry partnerships across market sectors (examples: materials, chemistry, biotechnology) | TA1: BioPrep, IV&V Partner |
| Nikolai Braun | Luna Labs USA | nikolai.braun@lunalabs.us | Charlottesville, VA | Luna Labs has developed biocompatible chemistries for reversible molecular caging and room-temperature preservation of living cells. Our platform has stabilized diverse eukaryotic cells, including endothelial, hepatic, fibroblast, and pigment cells. The same chemistry has enabled ambient stabilization of rabies vaccine and biomanufacturing enzymes, demonstrating broad applicability across diverse biologics. | We seek partners with expertise in bioprocess engineering, GMP manufacturing, and scalable instrument and device development to translate our proven biocompatible cell preservation technology into a deployable, user-friendly bioprocessing system. Ideal collaborators bring experience in aseptic system design, manufacturing readiness, and commercialization of biomanufacturing platforms. | TA1: BioPrep, IV&V Partner |
| Seth Cohen | U.C. San Diego | scohen@ucsd.edu | San Diego, CA | Metal-organic frameworks (MOFs), other porous solids, polymers that are well-suited for bioencapsulation (i.e., artificial biomineralization). | Experts in cell handling, storing, re-animating, as well as TA2. Collaborators that can use our expertise and methods in porous materials for encapsulation of cells and evaluate and scale them to achieve the goals of BoSS. | TA1: BioPrep |
| Han Xiao | RICE UNIVERSITY | han.xiao@rice.edu | Houston, TX | Our lab develops chemical and computational tools to engineer biomolecules with new functions. We use site-specific incorporation of unnatural amino acids and saccharide derivatives to probe, control, and therapeutically manipulate biological systems, particularly in cancer, autoimmune, and metabolic diseases. In parallel, we integrate machine learning with NGS-enabled protein evolution to map sequence–function relationships and design proteins with properties beyond those found in nature. | We seek teaming partners facing challenges in the biological stability of therapeutic or diagnostic molecules, such as rapid degradation, short half-life, or loss of activity. Ideal partners bring promising proteins, nucleic acids, or biomaterials whose clinical potential is limited by stability, and are interested in co-developing chemical and AI-enabled strategies to enhance robustness while preserving function. | TA1: BioPrep |
| Arun Subramanian | Shastrah | arun.subramanian@shastrah.ai | Bethesda, MD | We develop CNT-based sensor devices that measure biological VOC signals, along with the supporting hardware and data systems needed for real-world deployment. We are interested in conversations with teams working on complementary biological or materials technologies. | We are attending to better understand the BoSS program, its technical goals, and how teams engage with ARPA-H. We are open to informal conversations with researchers and organizations involved in the program to learn how our CNT-based sensing work may align with future opportunities. | TA2: Bioprocessing |
| Philip Norris | Vitalant Research Institute | pnorris@vitalant.org | San Francisco, CA | Our research institute is focused on immune cell function and engineering. Technologies available as research or cGLP include cell culture and rejuvenation, flow cytometry, scRNA-seq, functional assays, mouse models. The Biotherapies division of our company provides cell therapy starting material and qualification and is FACT accredited. Finally, our Vitalant Innovation Center supports clinical trial manufacturing and scale up. | For TA1 our research institute is looking to partner with basic chemistry labs to co-develop molecules such as biomimetics that will allow room temperature preservation of cell viability and function. We can provide starting cellular material and laboratory support through cell culture, preservation, and characterization. We would need to partner with a Bioprocessing partner to address TA2. | TA1: BioPrep, IV&V Partner |
| John Baust | CPSI Biotech | jmbaust@cpsibiotech.com | Owego, NY | CPSI Biotech focuses on molecular control of preservation-induced cell stress. We study stress-response activation during cryopreservation, hypothermia, and dry-state (anhydrobiotic) preservation, and develop recovery and re-animation reagents that modulate apoptotic, oxidative, and proteostatic pathways to improve post-storage cell viability and functional recovery. | Teams developing novel biostabilization processes or platforms seeking a TA1 partner to enable rapid post-preservation recovery. CPSI collaborates with groups requiring molecular-level re-animation solutions and biological guidance on recovery workflows to restore cell viability and function following dry-state, ambient, or low-temperature preservation. | TA1: BioPrep |
| Jason Fiering | Draper | jfiering@draper.com | Cambridge, MA | Draper is a non-profit R&D company with a proven track record of developing cell processing equipment. We partner with academics and biotech companies to advance new solution from concept to the clinic. Our expert technical team combines diverse and deep engineering expertise with proprietary cell poration, separation, and in-line sensing technologies to deliver fit-for-purpose prototypes and automated bioprocessing systems for use by pharma companies, research laboratories, and biotech CDMOs. | Draper seeks partners with expertise in chemistry and biology of cell stabilization to lead Tech Area 1. We are prepared to head a winning team and have decades of success leading government proposals and managing resulting grants and contracts, and we are open to joining other teams as an engineering and bioprocessing partner for Tech Area 2. Draper welcomes teaming with end users in cell therapy or related industries and with manufacturers of life science equipment for commercialization. | TA2: Bioprocessing |
| Tristan Clemons | University of Southern Mississippi | tristan.clemons@usm.edu | Hattiesburg, MS | The Clemons Lab at the University of Southern Mississippi is working on peptide based supramolecular polymer materials which can undergo hierarchical self-assembly into biomaterials capable of interfacing intimately with biological systems including cells, proteins, and nucleic acids. | The Clemons Lab has expertise and capabilities in peptide and polymer synthesis, soft matter characterization, electron microscopy and assessment of biological materials in the in vitro setting. We specialize in the synthesize of new polymeric materials and are seeking potential partners to support biological characterization, screening and assessment of potential solutions for novel BioStabilization Systems. | TA1: BioPrep |
| Christopher Wegener | Fresenius Kabi | Chris.Wegener@fresenius-kabi.com | Lake Zurich, IL | Automated, functionally closed systems (hardware, software, and single-use consumables) for GMP cell and gene therapy manufacturing, especially for cell formulation, fill, and finish for cryopreservation and other formulation. | Seeking partners who have strong understanding of the cellular/biological mechanisms for preservation and are in need of a means of implementation of clinical-scale, closed-system automation for cell preparation, formulation, and dispensing. | TA2: Bioprocessing, IV&V Partner |
| Timothy Rampiaray | Baigan, Inc. | timothyr4@baiganbox.com | New York City, NY | We develop scalable, closed-system platforms for stabilizing and transporting sensitive biological materials outside ultra-cold conditions. Our work focuses on system-level bioprocessing, hardware–software integration, environmental control, and workflow automation to enable reliable, manufacturable, and commercially deployable solutions for biologics handling and distribution. | We are seeking TA1 partners with deep expertise in cell biology, biostabilization chemistry, intracellular/extracellular protectants, and re-animation methods. Ideal partners bring validated biological approaches that can be integrated into scalable, closed bioprocessing systems, along with assay development and regulatory insight. | TA2: Bioprocessing |
| Param Singh | University of California, San Francisco | param.singh@ucsf.edu | San Francisco, CA | My lab studies the regulation of embryonic diapause in the African killifish, which is a unique vertebrate model of suspended animation. Killifish embryos survive years of desiccation at room temperature with full reanimation capability, preserving multiple vertebrate cell types and organs including heart, brain and muscle. We study specific genetic and metabolic switches that drive this reversible stasis, offering a blueprint to engineer similar resilience in human biologics. | We seek TA1 collaborators to test conserved genetic and chemical 'stasis triggers' in clinically relevant human cells, and TA2 partners to translate these vertebrate-conserved mechanisms into shelf-stable human products at scale. | TA1: BioPrep, TA2: Bioprocessing |
| Manwal Harb | MusiQ Bio | manwal@musiqbio.com | Dallas, TX | MusiQ Bio is developing MsQ, an ultrasound-triggered microbubble platform for intracellular delivery of protectant and intervention molecules. We focus on precise, noninvasive delivery across barriers such as cell membranes (in vitro) and even the blood-brain barrier (in vivo) to improve safety and efficacy of existing treatments. By combining cell-specific targeting with ultrasound activation, MsQ enables intracellular delivery within minutes while preserving cell integrity and function. | We are seeking partners working on molecules and products that need to be delivered intracellularly in low-resource settings within minutes for restoration, preservation or reanimation purposes. | TA1: BioPrep |
| Vincent Pham | Powerhouse Therapeutics | vincent@ph-therapeutics.com | San Antonio, TX | Powerhouse Therapeutics engineers allogeneic CAR T cells for solid tumors. Our lead construct, PH201, targets antigens common in GI tract malignancies and has shown preclinical efficacy in HCC and PDAC models. Our work centers on cell engineering, improving allogeneic performance, and understanding how these immune cells interact with the solid tumor microenvironment. | We seek collaborators with expertise in biostabilization chemistry, stress-tolerant biomolecules, and materials capable of enabling room-temperature preservation of immune cells. We are also interested in groups experienced in scalable bioprocessing, characterization assays, and technologies that complement our allogeneic CAR T engineering capabilities. | TA1: BioPrep |
| Sabrina Spencer | University of Colorado Boulder | sabrina.spencer@colorado.edu | Boulder, CO | Quantifying depth of cell-cycle withdrawal, the relationship between quiescence and senescence, and the likelihood that a cell will be able to re-enter the cell cycle | Groups interested in the fundamental biology governing reversible vs. irreversible stasis | TA1: BioPrep |
| Jeremiah Gassensmith | UT Dallas | jgassens@gmail.com | Dallas, TX | I develop metal–organic frameworks (MOFs) as active platforms for biopreservation, using biomimetic mineralization to stabilize fragile biological systems outside the cold chain. By growing reversible ZIF coatings around proteins, microbes, viruses, and complex assemblies, we preserve structure and function during ambient or cold stress while enabling on-demand recovery. This work includes DARPA-supported efforts to create deployable, field-ready MOF-based preservation technologies. | . | TA1: BioPrep |
| Larry Bartolotti | CGI | larry.bartolotti@cgifederal.com | Fairfax, VA | CGI Federal delivers complex biomanufacturing and R&D support, including digital bioprocess integration, eQMS/LIMS and GMP digital systems, data and quality management, and regulatory aware commercialization planning. We manage phased R&D portfolios, technoeconomic modeling, compliance workflows, PMO support, and stand-up compliant data/IT environments that enable GLP/GMP readiness, technology transition, and scale up of innovative cell manufacturing platforms. | CGI Federal is looking to support a partner with deep extremophile biology, biostabilization, and advanced cell handling expertise, including lab SOPs for ambient stabilization, re animation, and large scale GMP/GLP cell banking. We aim to complement a lead with hands on novel bioprocess hardware, IV&V facing wet lab test capability, sample logistics, and regulatory/clinical and commercialization strategy for next generation cell manufacturing. | TA2: Bioprocessing, IV&V Partner |
| Jan Nolta | University of California Davis Health | janolta@health.ucdavis.edu | Sacramento, CA | With its broad range of expertise in biology, human and veterinary medicine, UC Davis has built a strong foundation in Cell & Gene Therapy basic, translational and clinical Research. We have a large 6 suite GMP Facility in Sacramento, on the medical school/ UCD Health campus, a stem cell core, testing laboratory and other services available for partnering. We work with all human cell types and have extensive experience manufacturing and testing cells. | We look to partner by testing preserved cells for viability and function using specific in vitro attributes. | IV&V Partner |
| Paul Carman | CellFE Biotech | paul.carman@cellfebiotech.com | San Francisco, CA | CellFE is a U.S.-based life sciences company developing scalable, cell-friendly bioprocessing systems. Its proprietary VECT™ microfluidic platform enables rapid, uniform intracellular delivery while preserving cell viability and function. CellFE operates closed, single-use, GMP-compatible workflows processing tens of billions of cells in minutes across T cells (including resting), HSCs, iPSCs and MSCs. The platform serves as a general-purpose intracellular bioprocessing engine aligned with BoSS TA2 objectives. | CellFE seeks collaborators whose biostabilization strategies require or benefit from direct intracellular delivery. We are interested in intracellularly deliverable agents relevant to BoSS TA1, including protectants or intervention molecules, agents that modulate cell structure or stress responses, approaches that preserve intracellular complexity, and re-animation solutions. enabling rapid recovery of viability and function within closed, scalable workflows. | TA2: Bioprocessing, TA1: BioPrep |
| Mikhail Skliar | University of Utah | misha@chemeng.utah.edu | Salt Lake City, UT | The University of Utah offers a uniquely integrated environment for this work, combining a major medical school, academic hospital system, and strong programs in cell therapy, regenerative medicine, and basic health sciences. My lab operates within a culture of close collaboration among basic scientists, clinicians, and technology developers, supported by biomanufacturing facilities that enable translation of biomedical and life sciences discoveries into therapies and devices. | TA1: BioPrep, TA2: Bioprocessing | |
| Vrad Levering | Triple Ring Technologies | vlevering@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products in medtech and life sciences. Our interdisciplinary team (30% PhDs) excels in advancing technologies to FDA approval while working with academic partners. We have engaged with ARPA-H both as sub and multiparty. We offer capabilities in device and system integration, with experience in automated cell culture, cell sorting, assay dev, sample prep automation, and complex robotic and fluid management. ISO 13485 cert. | We partner with innovators to solve tough problems and create new businesses. From concept to FDA submission and commercialization, we handle technology development and redesign, as well as complex system integration. We are looking for teaming partners that could use our collaborative assistance to design enabling devices and technologies while navigating the FDA regulatory pathway. We have acted as primary, subcontractor, multiparty teammate, or vendor on previous submissions. | TA2: Bioprocessing, TA1: BioPrep |
| Joia Ramchandani | Artemia Bio | joiaram@gmail.com | Boston, MA | We leverage systems biology and functional genomics approaches to develop computationally-informed metabolic regulators for stabilizing cells. | We are looking for partners with expertise in biomanufacturing | TA1: BioPrep |
| David Jasek | Filament Consulting | djasek@filamentconsulting.org | London, UK | We support organisations involved in the development and manufacture of pharmaceutical products, including Cell & Gene Therapies. We have strong experience in method and product development for commercialisation, such as: QbD regulatory engagement, risk assessment and mitigation, QMS development and manufacturing plans. We are experts in Good Manufacturing Practice (GMP) and preparing organisations for regulatory approval and have worked with the FDA, EMA, MHRA and other global GMP regulators. | We seek technical partners who have an approach for Biostabilization Systems and require support to ensure that it can be successfully commercialised and approved by regulatory authorities. | TA2: Bioprocessing, TA1: BioPrep |
| Ian Pardo | Spires Quality | ian@spiresquality.co.uk | London | Spires Quality supports cell and gene therapy programmes from development to commercial supply by delivering: Method, material, and supplier support and assessment for commercial and regulatory readiness Product and organisational readiness and maturity: structure, governance, and risk management that stands up to scrutiny Regulator engagement: strategy and hands-on leadership for meetings, submissions, and inspections GMP compliance & aseptic assurance with a clear focus on product & patient | We seek to join a Team that has a strong technical approach that is ready for development and scaling towards commercialisation and regulatory submission. | TA2: Bioprocessing, TA1: BioPrep |
| Romel Menacho Melgar | Roke Biotechnologies | menachor@rokebio.com | Durham, NC | Roke Biotechnologies develops fast, scalable platforms for the production of recombinant proteins, with particular emphasis on VHH (nanobody) expression systems and chromatography-minimized purification workflows. Ongoing work includes development of therapeutic-relevant VHHs which can be used for stress and preservation studies. Due to their intrinsic thermal and chemical stability, VHHs provide an ideal low-risk case-study molecule for early-stage biostabilization development and validation. | We seek teaming partners developing novel preservation technologies for ambient storage of biologics, where Roke’s standardized protein and VHH production systems can enable rapid benchmarking, optimization, and scale-up. Collaboration modalities include (i) provision of therapeutic-relevant VHHs for stability and functional evaluation, and (ii) scalable supply recombinant proteins and enzymes used in stabilization, formulation, and validation workflows. | TA1: BioPrep, TA2: Bioprocessing |
| Robert Hart | INAEDIS | robert@inaedis.com | Princeton, NJ | Inaedis develops room-temperature aerosol dehydration technology to stabilize biologics, vaccines, and living cells without liquid nitrogen, enabling direct conversion of existing liquid formulations into stable powders. Founded by Princeton University-based scientists, the company aims to cut cold-chain costs, accelerate manufacturing timelines, enhance shelf life, and expand global access to advanced biologics and cell therapies through rigorous science and scalable GMP processes. | Inaedis seeks partners in: (1) primary cell biology and potency assays (T cells, MSCs, NK cells); (2) clinical cell therapy programs and translational centers; (3) GMP manufacturing and CMOs; (4) regulatory/CMC expertise for cell therapies; (5) strategic pharma/biotech partners for licensing and scale. All partners must be data-driven and committed to rigorous control of stabilization physics and biology. | TA2: Bioprocessing |
| Christopher Contag | Michigan State University | contagch@msu.edu | East Lansing, MI | Intracellular delivery of cell reprogramming factors to guide cell fates and functions in vivo | Packaging and delivery | TA1: BioPrep, TA2: Bioprocessing |
| Brantly Fulton | LAMAR Global | brantly1867@gmail.com | Los Angeles, CA | We provide the LAMAR FlexTag & InsightsOS platform, a 5G-enabled AI system that monitors temperature, humidity, and shock of critical biologics in transit. Our real-time tracking and predictive analytics ensure safe delivery, prevent product loss, and maintain supply chain integrity, supporting reliable access to fragile cell and gene therapies across complex and remote distribution networks. | LAMAR Global seeks partners with expertise in biologics production, cell and gene therapy development, and bioprocess engineering. Ideal collaborators bring experience in clinical scale manufacturing, regulatory compliance, and commercialization, complementing our real-time monitoring and predictive logistics to ensure safe, scalable, and efficient delivery of fragile biologics from manufacturer to patient. | TA2: Bioprocessing, TA1: BioPrep |
| Laszlo Kokai | American Chemical Society | koki.ce890601@gmail.com | Miskolc | SilvErgo is an adaptive nanosystem framework developed within Q-CPL's molecular control research line, designed to stabilize and protect biologically active drug payloads-particularly gene therapie vectors and macromolecular therapeutics-throughout the physical transportation process. | Controlled transport environments for biologicals and gene therapies. Nanoscale structural stability analytics under vibration and thermal stress. Biophysical modeling of vector preservation in logistics conditions. Translation of nanomatrix technology into regulatory-compliant drug-handling systems. | TA1: BioPrep, TA2: Bioprocessing |
| Nima Yazdanpanah | Procegence | nima@procegence.com | Chevy Chase, MD, USA, MD | We provide on-demand modeling and simulation services for product and process development, scale-up, and technology transfer. We have been helping many innovator and traditional organizations in the bio/pharmaceutical industry for rapid and efficient process development, scale-up, optimization, CMC, and regulatory submission. We are like a CRO for modeling and simulation services, and provide different modeling and simulation capabilities, expertise, and resources. | Teaming up with product and processes developer and provide modeling and simulation support for rapid ideation, scenario analysis, digital twin, and intelligent decision making. We provide a wide range of types of models from pure mechanistic, to data-driven, AI/ML, and hybrid models. We don't retain IP or license and our support is a fee-for-service business model. Teh team members don't need to develop costly and time-consuming in-house modeling capabilities. | TA2: Bioprocessing, IV&V Partner |
| Sinisa Hrvatin | Whitehead Institute/MIT | shrvatin@wi.mit.edu | Cambridge, MA | Hibernation - how animals initiate hibernation and how mammalian cells survive this state of stasis. Tardigrades - how they survive desiccation and freezing and whether human cells can survive similar states. We have candidate peptides/proteins/small molecules relevant to this proposal. | Formulations, manufacturing, GMP procedures. Access to clinically-relevant cell types and well established assays to test their potency. Commercialization. | TA1: BioPrep, TA1: BioPrep |